1. In Vivo
  2. >>Innovation

Running Ahead of the Pack in Technology Development

Device companies have historically kept innovation simple, giving doctors new tools that look and feel very much like what they've used in the past. But what happens when device innovation runs ahead of customers' willingness to adopt new technology?

In so doing, VP sheds new light on nearly a century of thinking about what causes acute myocardial infarctions, particularly in asymptomatic patients. If the VP proponents are right, these people often suffer heart attacks not because plaque gradually builds up inside coronary arteries until blood flow is blocked, but because inflamed macrophages cause plaque to erode and suddenly erupt, releasing thrombus.

What's amazing is how quickly physicians are jumping on the VP bandwagon. Maybe it's just wishful thinking, but companies developing...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Innovation

BioBytes: AI-Related Deals In Q3 ‘25

 
• By David Wild

The third quarter of 2025 included a host of venture financings for AI-focused biotechs and several $1bn+valued alliances.

ALS Drug Development Case Studies: MediciNova And Coya Therapeutics

 
• By David Wild

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

Beyond Data Sharing: How Biopharma Is Rewriting The Rules Of Collaboration

 
• By David Wild

Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.

How 250 Million Protein Measurements Could Transform Neurodegeneration Drug Development

 
• By Joanne Shorthouse

A massive new proteomics dataset promises to accelerate target identification, biomarker discovery and precision medicine approaches in Alzheimer's, Parkinson's and other neurodegenerative diseases.

More from In Vivo

Too Big To Refill? Pharma’s Race To Replace $300bn In Expiring Revenues

 
• By Daniel Chancellor

An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.

Beyond Cebranopadol: Tris Pharma’s 25-Year Legacy In Drug Delivery Innovation

 
• By David Wild

Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.

Beyond Data Sharing: How Biopharma Is Rewriting The Rules Of Collaboration

 
• By David Wild

Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.